Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2026)

Bicycle Therapeutics has reported Operating Leases for 8 years, with the latest figure at $13.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 431.77% year-over-year to $13.9 million; the trailing twelve-month figure through Mar 2026 stood at $13.9 million (up 431.77% YoY), and the FY2025 full-year result was $14.1 million, up 253.28% from the prior year.
• Operating Leases for Q1 2026 stood at $13.9 million, down from $14.1 million in the prior quarter.
• The five-year high for Operating Leases was $14.4 million in Q1 2023, with the low at $981000.0 in Q3 2025.
• Historically, Operating Leases has averaged $9.0 million across 5 years, with a median of $10.4 million in 2023.
• Annual changes were most pronounced in 2025 — Operating Leases sank 82.27% — and 2026, when it surged 431.77%.
• Bicycle Therapeutics' Operating Leases stood at $10.9 million in 2022, then retreated by 13.81% to $9.4 million in 2023, then plunged by 57.47% to $4.0 million in 2024, then surged by 253.28% to $14.1 million in 2025, then fell by 1.57% to $13.9 million in 2026.
• The last three Operating Leases figures came in at $13.9 million (Q1 2026), $14.1 million (Q4 2025), and $981000.0 (Q3 2025), per Business Quant data.